

AD _____

Award Number: DAMD17-02-1-0547

TITLE: Function of a Novel Signal Transduction Adapter Molecule
in Mammary Epithelia

PRINCIPAL INVESTIGATOR: Paul L. Stein, Ph.D.

CONTRACTING ORGANIZATION: University of Pennsylvania
Philadelphia, Pennsylvania 19104-6205

REPORT DATE: July 2003

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20031106 048

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 074-0188	
<small>maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503</small>				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE July 2003		3. REPORT TYPE AND DATES COVERED Annual (17 Jun 2002 - 17 Jun 2003)
4. TITLE AND SUBTITLE Function of a Novel Signal Transduction Adapter Molecule in Mammary Epithelia			5. FUNDING NUMBERS DAMD17-02-1-0547	
6. AUTHOR(S) Paul L. Stein, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Pennsylvania Philadelphia, Pennsylvania 19104-6205 E-Mail: steinp@mail.med.upenn.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) A significant fraction of breast cancer cell lines and primary tumors exhibit elevated Src tyrosine kinase activity. The mechanism(s) by which Src kinases become activated is not well understood. In some cases, these enzymes form complexes with various growth factor receptors, leading to their activation. Conceivably other gene products may act in a similar manner. We have cloned a novel adapter-like signaling molecule from epithelial cells that we call SRCASM, for <u>S</u> RC <u>A</u> ctivating and <u>S</u> ignaling <u>M</u> olecule. We hypothesize that elevated expression of SRCASM in mammary epithelia may result in increased Src activation, leading to hyperplasia or transformation. This will be studied by: (1) generation of transgenic mice expressing Srcasm in mammary epithelia. Mice will be monitored for changes in mammary gland morphogenesis as well as tumor development; (2) analyze mammary carcinoma cell lines and primary tumor samples to determine whether specific subset of tumors have elevated levels of Srcasm. The relative expression levels will be correlated with patient outcome or metastatic phenotype to determine whether monitoring Srcasm expression has any predictive value. Together these studies should provide insight into the function of Srcasm in mammary gland biology.				
14. Subject Terms (keywords previously assigned to proposal abstract or terms which apply to this award) oncogenes, signal transduction, cancer related biology, transgenic mice				15. NUMBER OF PAGES 5
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	5
Reportable Outcomes.....	5
Conclusions.....	5
References.....	NA
Appendices.....	NA

INTRODUCTION: A majority of breast cancer cell lines and primary tumors exhibit elevated tyrosine kinase activity, and a significant fraction of the kinase activity can be ascribed to increases in the specific activity of Src family kinases. The mechanism(s) by which Src kinases become activated is known for only a small percentage of tumors. In some cases, these enzymes form complexes with various growth factor receptors, leading to Src activation. This suggests that other gene products may interact with Src to promote its activation. We have cloned a novel adapter-like signaling molecule from epithelial cells that we call SRCASM, for SRC Activating and Signaling Molecule. Because of its unique biochemical properties, we hypothesize that elevated expression of SRCASM in mammary epithelia may result in increased Src activation and subsequent induction of hyperplasia or overt transformation. To investigate this further transgenic mouse that overexpress Srcasm in mammary tissue will be generated and analyzed to determine whether the cells develop a neoplastic fate. In addition, both human mammary cell lines and primary mammary tumor samples will be analyzed to determine if there is a correlation between tumor subtype and Srcasm expression.

BODY: Much of the first year was devoted to "reagent making". To this end, we have generated transgenic mice (Task I) designed to express SRCASM in mammary epithelia. Because we do not have antibodies that recognize the endogenous Srcasm protein, we cloned an epitope tagged version of SRCASM into a vector that drives expression from the MMTV LTR (promoter/enhancer). This construct has been used successfully to target expression of cDNAs to mammary tissue. At present we have seven transgenic founder lines. We are currently breeding them to determine which founders transmit the transgene to progeny and if they express the tagged protein.

We have also begun analyzing mammary cell lines and primary tissue for Srcasm expression (Task 3). As outlined in the original proposal we were going to perform in situ hybridization on archived breast cancer tissue. This procedure can be highly variable because much of the RNA may not be intact due to poor handling of tissue prior to embedment. To mitigate this problem as much as possible, we have altered the approach to focus more on measurements using quantitative RT-PCR. We have developed a sensitive assay and started analyzing samples. Of the cell lines tested, MCF-7 appears to express Srcasm at relatively high levels. To expand on the number of primary samples available we are also obtaining specimens from the Cooperative Human Tissue Network (CHTN). To date, we have analyzed approximately 20 normal and 20 cancerous samples. At present, no clear pattern has emerged. However, we are also trying to develop better, quicker assays. For example, the throughput can be increased if we have antibodies that specifically recognize endogenous Srcasm and work for immunohistochemistry. We now have two candidate rabbit polyclonal antibodies that are being characterized. In addition, we started making monoclonal antibodies. The hybridomas from the first fusion did not yield any antibodies that would work on Western blots (and therefore probably not be good candidates to further testing by immunohistochemistry). We then prepared a second fusion, which produced 5 candidate hybridomas. An initial screen of the new hybridomas showed that 2/5 recognized Srcasm by Western Blot. We are now characterizing the new antibodies in more detail to determine if they will be suitable as reagents for immunohistochemistry.

KEY RESEARCH ACCOMPLISHMENTS:

- Generated transgenic mice expressing Srcasm in mammary epithelia
- Begun characterizing relative SRCASM RNA levels in primary human tissue and cell lines using quantitative RT-PCR.
- Started making both rabbit polyclonal and mouse monoclonal antibodies to Srcasm to aid in the analysis of its expression in vivo.

REPORTABLE OUTCOMES:

None

CONCLUSIONS:

This work is designed to explore the function of Srcasm in the mammary gland. Specifically, we are interested in determining whether it can play a role in inducing mammary neoplasia. This is to be evaluated two ways. First, transgenic mice will be analyzed for development of mammary carcinoma. Second, primary human breast tissue and cell lines will be analyzed for Srcasm expression to determine if there is a correlation between tumor types and altered expression. We are trying to improve on the original approach by generating high quality antibodies that will recognize both endogenous and transgenically supplied Srcasm. If successful, we envision that the antibodies will enable us to rapidly screen large numbers of tissue sections for Srcasm expression.

REFERENCES:

N/A